| |
Move beyond a single set of forecast numbers and embrace uncertainty in healthcare forecasting: IQVIA’s Forecast Horizon is enabling pharma to broaden their analysis and drive deeper insights. Learn more. 
|
|
Today's Big NewsOct 6, 2022 |
Nearing a ‘watershed’ year, biosimilar industry gets a boost from Inflation Reduction Act Lilly inks $425M biobuck drug discovery pact with Schrödinger House lawmakers seek to limit CMS’ drug coverage authority after Aduhelm decision Abbott’s FreeStyle Libre cuts HbA1c in UK study Merck KGaA says it’ll consider ‘larger-scale’ acquisitions from 2023 onward |
| By Kevin Dunleavy A new provision in the recently signed Inflation Reduction Act should help spark the uptake of biosimilars. And considering the timing, it’s especially good news for the biosimilars industry as it readies for its most important test with the launch next year of several Humira copycats. The new IRA measure establishes an 8% add-on fee that Medicare Part B will pay (PDF) healthcare providers for qualifying biosimilars, replacing the previous 6% markup. |
|
|
|
By Nick Paul Taylor Eli Lilly has joined Schrödinger’s growing stable of drug development partners, putting up $425 million in milestones to access small-molecule candidates against an undisclosed target. |
By Robert King New bipartisan legislation seeks to curb CMS' drug coverage determinations in response to the agency's controversial decision on the Alzheimer's disease drug Aduhelm. |
By Conor Hale People with Type 1 diabetes were able to better control their blood sugar and reduce their HbA1c levels after six months, according to a study published in The New England Journal of Medicine. |
By Zoey Becker Merck KGaA has been investing heavily in its biopharma business as part of an effort to grow to 25 billion euros in global revenues by 2025. Starting next year, its expansion campaign could include M&A. |
By Max Bayer Cyclerion is shifting its clinical gears once more, divesting from targets in the central nervous system to focus instead on mitochondria-focused diseases. The pivot is resulting in layoffs for 45% of the workforce. |
By Conor Hale That amounts to five hits from the collaboration so far, with the latest additions aimed at chronic kidney disease and idiopathic pulmonary fibrosis. |
By Dave Muoio The nonprofit health system has been under fire for seeking payments from low-income patients who qualify for charity care. A representative recently told the New York Times that the charges were an "unintended error" and that refunds had been planned for months. |
By Sharon Klahr Coey AstraZeneca has imagined a swarm of annoying anthropomorphized eosinophils, a type of white blood cell which causes airway inflammation and asthma symptoms, mucking around and ruining everything in their path. |
By Nick Paul Taylor TauRx Pharmaceuticals is set to test the regulatory bar for approval of Alzheimer’s disease drugs in the post-Aduhelm world. The company was unable to show how its drug candidate performed compared to the control arm in a phase 3 clinical trial—but it plans to use the dataset to seek approval anyway. |
By Paige Minemyer A federal judge ruled late last week that Elevance Health must face a lawsuit that the federal government filed that alleges the insurer submitted inaccurate diagnostic data to juice its reimbursement in Medicare Advantage. |
By Gabrielle Masson Boehringer Ingelheim has its eyes on Surrozen, paying the California biotech $12.5 million cash for its preclinical asset designed to help regenerate healthy eye and potentially reverse retinal disease. |
By Fraiser Kansteiner The FDA blessed Eli Lilly's tirzepatide with a fast track designation as the company pursues an approval in obesity. The decision puts pressure on Novo Nordisk, whose own weight loss arriviste Wegovy largely has the obesity market to itself for now. |
Fierce podcasts Don't miss an episode |
| This week on "Podnosis," we talk about how how frequent cyberattacks are impacting patient care and what hospitals and health systems can do to shore up their defenses. Also under discussion is how social drivers of health are finally being recognized by the CMS. |
|
|---|
|
|
|
Monday, October 17, 2022 | 11am ET / 8am PT Join the Omic Revolution! Register now to attend a FREE webinar to leverage deep multiomic data integration for target and biomarker discovery. 
|
|
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT Data |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
